A meta-analysis is a potentially powerful tool to summarize results from separate, however, closely related research projects. Meta-analyses are conducted at negligible costs and efforts as compared to those required for the acquisition of new raw data, e.g., by clinical trials. As part of systematic assessment of drug effects, meta-analyses form the basis for evidence-based clinical decision making and, moreover, are also used by policy makers, e.g., to determine reimbursement. These benefits have increasingly been recognized in recent years.
that no specific in-depth expertise is required to conduct a meta-analysis, neither medical nor statistical nor pharmacological. Because of the need for information for decisionmaking and the excellent reception of meta-analyses, becoming a "meta-analyst" may seem as an intriguing idea to easily acquire many impact points and reputation and make a splendid career, with the excellent cost to benefit ratio of metaanalysis extending to the "meta-analyst" as an individual scientist-or does it?
Some researchers and some science policy makers certainly would agree, although in 2014 published meta-analyses accounted for not more than about 1.3 % of all publications in PubMed (http://www.ncbi. nlm.nih.gov/pubmed/, accessed March 8, 2015). For several years, editors of many journals including the European Journal of Clinical Pharmacology are virtually flooded with meta-analyses. This phenomenon is not limited to the area of clinical pharmacology [1] . The annual exponential increase of published metaanalyses calculated from 1990 to 2014 is pretty constant (Fig. 1) . It reaches 1.17-fold (8 %) and considerably exceeds the 1.04-fold (2 %) increase seen for all publications (given as geometric mean and coefficient of variation). From our perception, the number of submitted manuscripts reporting a meta-analysis is growing even faster. The technical/statistical quality of submitted meta-analyses is typically high and shows proper use of the tools available. Does clinical pharmacology or, more generally, biomedical science benefit from this phenomenon?
From a scientific point of view, the appropriate starting point for a meta-analysis is a specific research question which has been addressed by a variety of individual research projects, however, which has not been answered with sufficient precision by any of these, say, because individual projects were not large enough.
Existing information however typically should be sufficient to generate a specific hypothesis, also taking clinical relevance into account where applicable. For instance, to demonstrate that treatment A is as effective in lowering blood pressure as treatment B, "as effective as" needs to be well defined beforehand, e.g., as "with 95 % confidence, difference in systolic blood pressure reduction is not larger than 5 mmHg." If a metaanalysis is part of a data-mining process in absence of a guiding hypothesis, this should be clearly described and justified.
Which studies can be considered as addressing a similar research question? Would it be sensible to summarize the effects of any "antihypertensive therapy" in a meta-analysis? Or the effects of any beta-blocker? Of those of the beta-blocker metoprolol at any dose? The answer would be different for different response criteria, such as blood pressure-lowering effect or emergence of hypoglycemia in diabetics. Provided the selection criteria of individual studies to be included in a metaanalysis are covered, the detailed rationale for this selection should also be integral part of an eventually published meta-analysis.
How many studies are required to make conduction of a meta-analysis sensible? If two studies are almost identical with regard to study design and covariates, a number of two might be sufficient. Like for studies in individual patients, increasing variability between studies results in a larger number required to test the hypothesis. It remains to be addressed whether an average effect of a specific drug treatment calculated from a large number of heterogeneous studies conducted on different populations is of any clinical use, because at the end of the day, the average result cannot be applied to a patient belonging to one of these populations. Thus, once all studies fulfilling the selection criteria have been identified, the next step to be addressed and to be described in a manuscript is whether observed heterogeneity is appropriate for the conduction of the intended meta-analysis.
An appropriate meta-analysis is original research because it uses specific methods and provides novel information, and the process of its generation is as vigorous as experimental research. Accordingly, the process should be described prior to its start in a respective protocol as recently recommended in detail [3] . Such protocols should be registered "in order to promote and maintain transparency in the systematic review process, to assist in minimizing the risk of bias(es), and help to reduce unnecessary duplication of reviews" [3] . Proper reporting of meta-analysis of clinical trials is covered by the broadly accepted recommendations [2, 4] . For meta-analysis on pharmacological interventions, additional key information of individual research projects includes exposure towards the drug(s) to be examined, i.e., substance, dose, route of administration, and duration of treatment. Potential covariates such as demographic characteristics, disease state, co-medication, etc. of individual research projects included in the analysis should be described in sufficient detail.
Many of the manuscripts on meta-analyses submitted to the European Journal of Clinical Pharmacology appear to reveal a different procedure and seem to be driven primarily not by scientific but rather by publication motivations. To this end, the starting point is to identify any area where a new metaanalysis could be accepted for publication. Identifying respective gaps of knowledge is very challenging and highly competitive task, especially without detailed knowledge in the respective medical area, because most evidence which can reasonably be summarized was already meta-analyzed. The result often is without benefit for the scientific community. Undesired but frequent attempts include but are not limited to the following: The European Journal of Clinical Pharmacology continues to welcome the submission of manuscripts reporting highquality meta-analyses irrespective of geographic origin. We recently adopted our "instructions of authors" to clarify our expectations. As outlined above, beyond being technically/ 
